$JBIO News

Jade Biosciences Enters Exclusive Worldwide License Agreement With Paragon Therapeutics; To Pay Up To $22M In Milestone Payments To Paragon; To Pay Paragon Low To Mid-Single-Digit Percentage Royalties On Net Sales Of Licensed Products; Paragon Barred From New Campaigns Targeting Licensed Target For At Least Five Years

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors

UBS Initiates Coverage On Jade Biosciences with Buy Rating, Announces Price Target of $45

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Reported Earlier, Jade Biosciences Prices $150M Stock Offering Of 10M Shares at $15 Each

Jade Biosciences Announces Pricing of Public Offering of Common Stock

Jade Biosciences Announces Proposed Underwritten Public Offering

Jade Biosciences Reveals Proposed Underwritten Public Offering; No Size Disclosed

Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $45

Jade Biosciences: Strong Early Signal, But Still A Wait For Proof

Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials

Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript

Why Is Jade Biosciences Stock Trading Lower On Monday?

BTIG Maintains Buy on Jade Biosciences, Raises Price Target to $74

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

HC Wainwright & Co. Maintains Buy on Jade Biosciences, Raises Price Target to $55

jade Biosciences Announces Interim Results From Its Phase 1 Trial Evaluating JADE101, A Novel, Investigational AntI-A Proliferation-Inducing Ligand Monoclonal Antibody In Development For The Treatment Of Immunoglobulin A Nephropathyl; JADE101 Showed Favorable Safety Profile And Well-Tolerated Across All Evaluated Subcutaneous Dose Levels

Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy

Jade Biosciences To Present Phase 1 JADE101 Data In Conference Call On June 1, 2026 At 8:00 a.m. ET

Assessing Jade Biosciences (JBIO) Valuation After Recent Share Price Weakness And Longer Term Gains